Journal Article

P206 Effectiveness of tezepelumab treatment in patients with severe asthma: real world outcomes from a severe asthma network

Marsh, J, Sutton, B, Berair, R, Khan, S, Matonhodze, M, Verrier, E, White, L, Mansur AH, Gilbey, S, Ryan, P, Doherty, M, Sheego, M, Drew, M, Sullivan, J, Message, S, Mehmood, T, Subramanian, D, Idris, E, Lyng, E, Pillai, A, Barker, B

2025

Overview

IntroductionRandomised clinical trials confirmed efficacy of Tezepelumab in treatment of severe asthma, but real-world data on its performance remains limited. This study evaluated its effectiveness in routine clinical practice across our networkMethodologyThis retrospective, observational study was conducted across nine hospital sites in central England. Eligible patients under NICE guidance were initiated on Tezepelumab following regional MDT approval. Treatment outcomes at 12 months were classified as positive (≥50% reduction in exacerbation frequency or maintenance oral corticosteroid [mOCS] dose) or negative, with early discontinuation of treatment recorded. Clinical remission was defined as: no severe exacerbations, off mOCS, and asthma control questionnaire (ACQ-6) score <1.5. Data was extracted from structured proformas. Standard and descriptive statistics were performed.ResultsA total of 145 patients with severe asthma initiated on Tezepelumab were included in the analysis. Baseline clinical and phenotypical characteristics are summarised in table 1. Positive outcomes were seen in 67% (n=97/145), 7% (n=10/145) had borderline responses requiring review at 18 months, and 26% (n=38) discontinued due to negative response, which included adverse effects such as rash, arthralgia and myalgia, neurological symptoms, and fatigue (10%, n=13/145).In patients with paired baseline and 12-month data (n=125), median annual exacerbations fell from 5.0 (4.0–7.0) to 1.0 (0.0–2.25) (p<0.0001), and maintenance OCS from 10.0 (7.50–15.0) to 5.0 (0.0–10.0) mg/day (p<0.0001) among those on OCS at baseline (n=44). ACQ-6 significantly improved from 3.67 (2.67–4.64) to 2.17 (1.00–4.05) (p<0.0001), and proportion of well-controlled asthma (ACQ-6 <1.5) rose from 3.5% (n=4/116) to 38% (n=44/116) (p=0.03). FEV1significantly increased from 2.22 (1.44–2.71) to 2.44L (1.76–3.02) (p<0.0001). FeNO declined from 25.0 (12.0–59.8) to 18.0 (11.0–29.0) ppb (p<0.0001), blood eosinophil count from 0.23 (0.11–0.45) to 0.14 (0.07–0.24) x109/L (p<0.0001), and total IgE (n=26) from 192.0 (34.0–410.1) to 67.5 (18.0–169.0) (p=0.0002).The proportion who achieved clinical remission at 12 months were 22% (n=27/125).Abstract P206 Table 1Baseline clinical and phenotypical characteristics. *Data missing for 3 patientsConclusionsTezepelumab led to significant improvements in OCS use, asthma control, and T2 markers in a real-world setting. Two-thirds of patients had a positive response, with a subset (22%) achieving clinical remission, demonstrating clinical benefits of Tezepelumab in managing severe asthma in routine care.

• Publisher: BMJ Publishing Group LTD
• Subject: Asthma / Remission (Medicine)